Literature DB >> 11328267

Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils--a study using intravital videomicroscopy.

H Suzuki1, M Mori, K Seto, M Miyazawa, A Kai, M Suematsu, T Yoneta, S Miura, H Ishii.   

Abstract

BACKGROUND: We previously demonstrated that Helicobacter pylori colonization evokes gastric mucosal inflammation and an extensive increase in lipid peroxides and glutathione in Mongolian gerbils. Zinc and its derivative, polaprezinc, have been reported to be potent antioxidants in gastric mucosa. AIM: To examine the effect of polaprezinc on gastric mucosal oxidative inflammation in H. pylori-colonized Mongolian gerbils.
METHODS: Sixty-eight male Mongolian gerbils were orally inoculated with H. pylori (ATCC43504, 5 x 10(8) CFUs/gerbil; H. pylori group) and 35 gerbils were inoculated with the culture media (control group). Twenty-two gerbils in the H. pylori and 13 gerbils in the control group were fed with diets containing polaprezinc (0.06%, 100 mg/kg, 10 times the usual clinical dose) (H. pylori + polaprezinc group, polaprezinc group). The remaining gerbils were fed a standard laboratory chow diet. Neutrophil infiltration, assessed histologically and by the activity of myeloperoxidase, the contents of CXC-chemokine (GRO/CINC-1-like protein) and the contents of thiobarbituric acid-reactive substances, was evaluated in each group 12 weeks after the inoculation. Separately, gastric mucosal leucocyte activation and capillary perfusion were also assessed using intravital microscopy 2, 4, 8 and 12 weeks after the inoculation.
RESULTS: In all H. pylori-inoculated animals, the bacterial infection persisted throughout the experimental period. Gastric mucosal lesion formation in the H. pylori group was significantly inhibited in the H. pylori + polaprezinc group. Elevated levels of myeloperoxidase activity, GRO/CINC-1 and thiobarbituric acid-reactive substances in the H. pylori group at 12 weeks were attenuated significantly by polaprezinc treatment. Enhanced levels of venular leucocyte activation observed in the H. pylori group were attenuated significantly in the H. pylori + polaprezinc group during both the early phase (2 weeks) and late phase (12 weeks).
CONCLUSION: Polaprezinc inhibited H. pylori-associated gastric mucosal oxidative inflammation, including initial micro-vascular leucocyte activation, in Mongolian gerbils.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328267     DOI: 10.1046/j.1365-2036.2001.00960.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

1.  Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury.

Authors:  Tatsushi Omatsu; Yuji Naito; Osamu Handa; Katsura Mizushima; Natsuko Hayashi; Ying Qin; Akihito Harusato; Ikuhiro Hirata; Etsuko Kishimoto; Hitomi Okada; Kazuhiko Uchiyama; Takeshi Ishikawa; Tomohisa Takagi; Nobuaki Yagi; Satoshi Kokura; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  J Gastroenterol       Date:  2010-02-20       Impact factor: 7.527

Review 2.  Overview: Helicobacter pylori and extragastric disease.

Authors:  Hidekazu Suzuki; Barry James Marshall; Toshifumi Hibi
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

3.  Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats.

Authors:  Reina Ohba; Michiro Otaka; Masaru Odashima; Mario Jin; Koga Komatsu; Noriaki Konishi; Isao Wada; Youhei Horikawa; Tamotsu Matsuhashi; Jinko Oyake; Natsumi Hatakeyama; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

4.  Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.

Authors:  Hajime Isomoto; Hisashi Furusu; Ken Ohnita; Chun-Yang Wen; Kenichiro Inoue; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 5.  Helicobacter pylori: a ROS-inducing bacterial species in the stomach.

Authors:  Osamu Handa; Yuji Naito; Toshikazu Yoshikawa
Journal:  Inflamm Res       Date:  2010-09-05       Impact factor: 4.575

Review 6.  Carbohydrate-dependent defense mechanisms against Helicobacter pylori infection.

Authors:  Motohiro Kobayashi; Heeseob Lee; Jun Nakayama; Minoru Fukuda
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

Review 7.  Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Takanori Kanai; Naohisa Yahagi
Journal:  J Clin Biochem Nutr       Date:  2014-12-27       Impact factor: 3.114

8.  Helicobacter pylori urease activates blood platelets through a lipoxygenase-mediated pathway.

Authors:  German E Wassermann; Deiber Olivera-Severo; Augusto F Uberti; Célia R Carlini
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310

Review 9.  Zinc, Carnosine, and Neurodegenerative Diseases.

Authors:  Masahiro Kawahara; Ken-Ichiro Tanaka; Midori Kato-Negishi
Journal:  Nutrients       Date:  2018-01-29       Impact factor: 5.717

10.  Different Metabolites of the Gastric Mucosa between Patients with Current Helicobacter pylori Infection, Past Infection, and No Infection History.

Authors:  Su-Young Son; Choong-Hwan Lee; Sun-Young Lee
Journal:  Biomedicines       Date:  2022-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.